Sodium Iodide [123i] Ge Healthcare

Sodium Iodide [123I] from GE Healthcare is a radiopharmaceutical used in diagnostic imaging. This non-therapeutic agent helps visualize thyroid function and structure. Suitable for intravenous administration in nuclear medicine. Short half-life ensures rapid clearance from the body.

Sodium Iodide [123I] is primarily used for diagnostic imaging of the thyroid gland. It helps assess thyroid function and detect abnormalities such as nodules or hyperthyroidism. This radiopharmaceutical is also employed in whole-body scans to evaluate metastatic thyroid cancer. Its radioactive iodine content enables precise imaging without therapeutic intent.

After intravenous administration, Sodium Iodide [123I] is absorbed by the thyroid gland, where it emits gamma radiation detectable by imaging equipment. The radioactive signal provides detailed images of thyroid tissue, aiding in the identification of functional or structural issues. Effects are temporary, as the isotope decays and clears from the body within hours.

Handle Sodium Iodide [123I] with care due to its radioactive properties. Use appropriate shielding and follow radiation safety protocols during preparation and administration. Pregnant or breastfeeding individuals should avoid exposure. Ensure proper disposal of materials to prevent environmental contamination.

Certain medications, such as thyroid hormones or antithyroid drugs, may interfere with the uptake of Sodium Iodide [123I]. Contrast agents containing iodine can also affect imaging results. Avoid consuming foods or supplements high in iodine prior to administration. Consult a healthcare provider for guidance on concurrent medications.